“The importance of species selection to predict
the human safety of biopharmaceuticals ”
Thursday 11 May 2017
Janssen Pharmaceuticals, Beerse, Belgium
Programme
| 8:30-9:00 | Coffee |
| 9:00-9:10 | Welcome M. Cornet, President of BelTox |
| Morning session: Lectures | |
| 9:10-9:40 | Species selection for the non-clinical testing of Biologicals I Andreini. RTC, Italy |
| 9:40-10:10 | Importance of the nonhuman primate in the assessment of Biologicals S. Grote-Wessels, Covance Munster, Germany |
| 10:10-10:40 | Coffee break and networking |
| Examples | |
| 10:40-11:05 | Alternative approaches to preclinical safety assessment when you have no standard tox species S. Marshall, Envigo, UK |
| 11:05-11:30 | Contribution of immunohistochemistry and tissue cross reactivity to species selection F. Gervais, CitoxLab, France |
| 11:30-11:55 | Are effects in non-clinical species translating into humans ? A. Cauvin, UCB Biopharma, Belgium |
| 11:55-12:20 | Animal models to evaluate vaccine-induced enhanced disease in RSV and other infectious diseases R. Zahn, J&J, The Netherlands |
| 12:20-12:40 | Panel discussion |
| 12:40-13:45 | Lunch and networking |
| Afternoon session: Case studies analysis | |
| 13:45-13:55 | Introduction to breakout sessions |
| 13:55-15:00 | Breakout sessions |
| 15:400-15:30 | Coffee break and networking |
| 15:30-16:30 | Case study reporting and discussion |
| 16:30-16:40 | Concluding remarks |
Organizing Committee:
Annick Cauvin and Miranda Cornet (UCB Biopharma), Judith Baumeister and Frédérique Delannois (GSK Vaccines), Miek Desmidt, Ad Knaapen and Kristel Steemans (Johnson & Johnson), Andreas Hohlbaum (Ablynx)
To download the program, please use the attachment below:
5th Beltox Workshop Safety Assessment Biopharm – 11 May 2017 – Programme